Amendment Statement of Principles
concerning
DIABETES MELLITUS
(Reasonable Hypothesis)
(No. 49 of 2022)
The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.
Dated 29 April 2022
The Common Seal of the
|
Professor Terence Campbell AM Chairperson
|
Contents
2 Commencement
3 Authority
4 Amendment
1 Name
This is the Amendment Statement of Principles concerning diabetes mellitus (Reasonable Hypothesis) (No. 49 of 2022).
This instrument commences on 30 May 2022.
This instrument is made under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.
The Statement of Principles concerning diabetes mellitus (Reasonable Hypothesis) (No. 48 of 2020) (Federal Register of Legislation No. F2020L00823) is amended in the following manner:
Section | Amendment |
9(6)(g) | Replace the existing factor in subsection 9(6)(g) with the following: taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of diabetes mellitus; Note: immune checkpoint inhibitor is defined in the Schedule 1 – Dictionary. |
9(13a) | Replace the existing factor in subsection 9(13a) with the following: taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of diabetes mellitus; Note: immune checkpoint inhibitor is defined in the Schedule 1 – Dictionary. |
Schedule 1 – Dictionary | Insert the following definition of "immune checkpoint inhibitor" in alphabetical order: immune checkpoint inhibitor means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab.
|